Aurobindo, which is one of the largest generic drug makers, has halted some production at a key facility in India after U.S. inspectors found manufacturing problems, the latest such episode to underscore concerns over both shortages and the quality of medicines produced by some suppliers.
In a notice filed with the Bombay Stock Exchange, the company reported that the U.S. Food and Drug Administration identified nine different quality-control issues at a plant run by its Eugia Pharma Specialties subsidiary in Telangana, India. The inspection, which ended on Feb. 2, prompted Aurobindo to temporarily halt manufacturing on an undisclosed number of production lines.
The drugmaker added that consultants have already been hired to fix the problems, which were not specified, and hopes to restart production as soon as possible, although no timetable was provided. “At this point in time, we don’t foresee any material impact on the business,” Aurobindo executives maintained in the notice filed with the exchange.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect